AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Shares in Celcuity climbed by 233.76% at market open on 28 July after it reported the Phase III breast cancer data.

Recognify Life Sciences has reported that its Phase IIb trial of inidascamine to treat CIAS failed to achieve its primary goal.

Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.

Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.

Abivax's obefazimod resulted in an average 16.4% placebo-adjusted clinical remission rate in UC patients across the two trials.